Equities

Excelsior Medical Co Ltd

4104:TAI

Excelsior Medical Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (TWD)88.80
  • Today's Change0.00 / 0.00%
  • Shares traded114.86k
  • 1 Year change+2.01%
  • Beta--
Data delayed at least 20 minutes, as of Jul 30 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

EXCELSIOR MEDICAL CO., LTD. is a Taiwan-based company principally engaged in the distribution, maintenance and leasing of medical equipment and supplies. The Company’s principal products include artificial kidneys, hemodialysis blood tubing sets and epidural needles, dialysis liquid medicines and powder medicines, dialysis machines, human erythropoietin, surgery consumable materials, blood bags, plasma replacement machines and beauty medical equipment, among others. The Company is also involved in the production and sales of self-owned soybean milk machines, as well as household air fresheners under the brand name of Coway. The Company mainly operates its businesses in domestic market and overseas markets.

  • Revenue in TWD (TTM)8.27bn
  • Net income in TWD729.96m
  • Incorporated1988
  • Employees774.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SciVision Biotech Inc787.96m196.83m7.27bn64.0039.824.7027.969.232.672.6710.3322.670.36012.148.34--9.006.6710.097.4174.1369.9424.9825.002.90--0.173979.7427.9316.6925.5315.41-31.1611.38
CHC Healthcare Group3.73bn341.88m7.79bn160.0025.171.268.442.091.861.8619.9736.920.27534.083.97--2.523.233.003.8026.3730.129.1513.162.0110.780.45581.7530.359.1117.475.319.692.25
Excelsior Medical Co Ltd8.27bn729.96m13.82bn774.0019.001.6611.901.674.674.6752.9653.650.47065.365.48--5.144.9410.499.2520.2520.2210.9110.601.28--0.091483.2214.565.3511.8610.5831.537.24
Vizionfocus Inc2.83bn654.83m13.92bn--19.934.3513.254.9212.1412.1452.6055.630.64016.996.07--17.0312.0022.0016.5440.9037.0126.6020.522.90--0.279528.7340.2352.1879.65233.8971.42--
Taidoc Technology Corp4.35bn1.02bn15.50bn829.0015.191.6712.093.5710.7010.7045.4397.110.34681.953.98--8.5117.6011.7322.9840.6350.7324.5528.493.14--0.065968.99-50.072.03-69.933.02-34.714.58
Visco Vision Inc2.69bn432.93m16.10bn--37.245.3819.335.996.866.8642.6047.460.53972.855.99--8.5611.6811.1715.8039.4040.5615.8617.721.1621.320.270743.00-13.6825.82-51.158.740.8293--
Data as of Jul 30 2024. Currency figures normalised to Excelsior Medical Co Ltd's reporting currency: Taiwan Dollar TWD

Institutional shareholders

2.07%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 04 Jul 20242.47m1.59%
Acadian Asset Management LLCas of 30 Sep 2023237.76k0.15%
SSgA Funds Management, Inc.as of 03 Jul 2024175.73k0.11%
American Century Investment Management, Inc.as of 03 Jul 2024139.50k0.09%
Dimensional Fund Advisors Ltd.as of 31 May 2024130.13k0.08%
DFA Australia Ltd.as of 30 Jun 202467.06k0.04%
FIL Investments Internationalas of 30 Jun 20231.85k0.00%
LGT Capital Partners AG (Investment Management)as of 30 Nov 20230.000.00%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.